| Theme | Best Available Managements of Helicobacter pylori Gastritis | |
|---|---|---|
| Title | Treatment for Patients Refractory to 1st and 2nd Line Regimens | |
| Publish Date | 2014/03 | |
| Author | Takahisa Furuta | Center for Clinical Research, Hamamatsu University School of Medicine |
| Author | Mitsushige Sugimoto | First Department of Medicine, Hamamatsu University School of Medicine |
| Author | Takahiro Uotani | First Department of Medicine, Hamamatsu University School of Medicine |
| Author | Shu Sahara | First Department of Medicine, Hamamatsu University School of Medicine |
| Author | Hitomi Ichikawa | First Department of Medicine, Hamamatsu University School of Medicine |
| Author | Takuma Kagami | First Department of Medicine, Hamamatsu University School of Medicine |
| [ Summary ] | Recent reports have suggested that the candidates for third rescue regimens to treat H. pylori infection in Japan should be treated with fluoroquinolone-based regimens and dual therapy consisting of high doses of a proton pump inhibitor, and amoxicillin. Of fluoroquinolones, sitafloxacin has equally strong anti-H. pylori effects as AMPC and is effective in treating strains resistant to levofloxacin. Sitafloxacin-based regimens have been reported to yield relatively sufficient eradication rates when used for as the third line therapy. Dual therapy with high doses of a proton pump inhibitor and amoxicillin has also been reported to provide sufficient rescue rates. To achieve high rescue eradication rates, eradication regimens must be designed based on well-understanding of reasons for eradication failure, such as bacterial resistance patterns, as well as the pharmacological characteristics of agents used for H. pylori eradication therapy. | |